Omeros Corporation

OMER Healthcare Biotechnology

Revenue
+35.5%
EPS
+141.9%
Free cash flow
+118.7%
Total debt
−42.0%

Quarter to June 2026, against a year earlier

16.83 0.24 −1.41%
Market cap
$1.2B
P/E
9.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
2/9
Altman Z
−6.82
Beneish M
−0.06
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
— — — — — 2 4 1 5 6
P/E ratio
— — — — — 0.00 0.00 0.00 0.00 0.00
P/S ratio
— — — — — 11.07 6.24 18.12 14.16 9.82
Altman Z-Score
— — — — — (6.82) (8.09) (10.72) (1.68) (8.73)
Altman Z″-Score (non-manufacturers)
— — — — — (17.81) (22.80) (26.90) (12.60) (24.26)
P/FCF ratio
— — — — — 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — — — (0.06) (3.11) (2.79) (2.25)
P/Operating CF
— — — — — (44.39) (30.32) (21.95) (220.05) (37.61)
P/B ratio
— — — — — 0.00 0.00 0.00 0.00 0.00
EV/Sales
— — — — — 12.49 7.14 21.08 14.16 10.64
EV/EBITDA
— — — — — 0.00 0.00 0.00 0.00 0.00
EV/FCF
— — — — — (9.19) (13.22) (6.04) (25.09) (8.57)
Current Ratio
2.76 1.69 4.09 3.25 4.79 4.12 1.87 2.41 4.12 3.75
Net Debt/EBITDA
(0.30) (0.57) (0.26) (0.75) (0.94) (0.68) (0.70) (0.80) 0.00 (0.64)
Debt/Equity
(1.72) (1.03) (8.53) 3.68 13.40 (1.99) (1.48) (1.50) (29.78) (2.13)
ROE
2.21% 151.08% (388.17%) 86.63% (400.60%) 120.17% 80.78% 246.20% 265.67% 209.62%
ROA
(1.11%) (47.86%) (24.31%) 9.39% 64.71% (86.83%) (72.55%) (119.43%) (58.26%) (114.81%)
ROIC
0.00% 0.00% (629.94%) (49.56%) (58.58%) 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(2.40%) (273.81%) (70.74%) 15.38% 98.15% (117.90%) (162.11%) (224.92%) (63.53%) (147.11%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 278.85 96.53 105.57
Earnings Yield
— — — — — (16.79%) (12.07%) (23.43%) (5.80%) (16.34%)
Free Cash Flow Yield
— — — — — (12.28%) (8.66%) (19.27%) (3.98%) (12.65%)
Free Cash Flow per Share
(1.83) (2.56) 1.18 (1.38) (1.76) (1.76) (1.22) (2.15) (0.80) (1.28)
Book value per Share
(1.91) (3.14) (0.40) 1.37 0.38 (2.11) (2.20) (2.06) (0.06) (0.93)
Free Cash Flow
(116.16) (148.97) 74.30 (86.60) (110.00) (100.37) (60.41) (104.30) (36.58) (51.63)
EV/EBIT
— — — — — 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026